A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

Vikas Gupta, Ruben Mesa, Michael W.N. Deininger, Candido E. Rivera, Shireen Sirhan, Carrie Baker Brachmann, Helen Collins, Jun Kawashima, Yan Xin, Srdan Verstovsek

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, nonrandomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A total of 61 subjects with primary myelofibrosis or post–polycythemia vera/post–essential thrombocythemia myelofibrosis with intermediate- or high-risk disease received momelotinib. A phase 1 dose escalation identified 200 mg twice daily as the optimal dose to be expanded in phase 2. The most frequent adverse events were diarrhea (45.9%), peripheral neuropathy (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%), the latter primarily due to a first-dose effect. The response assessment according to the 2006 International Working Group criteria (≥8 weeks duration at any time point) demonstrated spleen response by palpation of 72% (36/50) and anemia response of 45% (18/40). Spleen response by magnetic resonance imaging obtained at 24 weeks was 45.8% (27/59) for all subjects and 54.0% (27/50) for those with palpable splenomegaly at baseline. The symptoms of myelofibrosis were improved in most subjects. Cytokine analysis showed a rapid decline in interleukin-6 with momelotinib treatment, and a slower reduction in other inflammatory cytokines. In the subgroup of subjects with the JAK2V617F mutation at baseline (n=41), momelotinib significantly reduced the allele burden by 21.1% (median) at 24 weeks. These results provide evidence of tolerability and a potential therapeutic activity of momelotinib for subjects that support further evaluation in ongoing, phase 3 randomized trials.

Original languageEnglish (US)
Pages (from-to)94-102
Number of pages9
JournalHaematologica
Volume102
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Janus Kinase 1
Spleen
Janus Kinase 2
Cytokines
Thrombocytosis
Palpation
Splenomegaly
Dizziness
Peripheral Nervous System Diseases
Thrombocytopenia
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
Anemia
Diarrhea
Interleukin-6
Therapeutics
Alleles
Magnetic Resonance Imaging
Safety
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Gupta, V., Mesa, R., Deininger, M. W. N., Rivera, C. E., Sirhan, S., Brachmann, C. B., ... Verstovsek, S. (2017). A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Haematologica, 102(1), 94-102. https://doi.org/10.3324/haematol.2016.148924

A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. / Gupta, Vikas; Mesa, Ruben; Deininger, Michael W.N.; Rivera, Candido E.; Sirhan, Shireen; Brachmann, Carrie Baker; Collins, Helen; Kawashima, Jun; Xin, Yan; Verstovsek, Srdan.

In: Haematologica, Vol. 102, No. 1, 01.01.2017, p. 94-102.

Research output: Contribution to journalArticle

Gupta, V, Mesa, R, Deininger, MWN, Rivera, CE, Sirhan, S, Brachmann, CB, Collins, H, Kawashima, J, Xin, Y & Verstovsek, S 2017, 'A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis', Haematologica, vol. 102, no. 1, pp. 94-102. https://doi.org/10.3324/haematol.2016.148924
Gupta, Vikas ; Mesa, Ruben ; Deininger, Michael W.N. ; Rivera, Candido E. ; Sirhan, Shireen ; Brachmann, Carrie Baker ; Collins, Helen ; Kawashima, Jun ; Xin, Yan ; Verstovsek, Srdan. / A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. In: Haematologica. 2017 ; Vol. 102, No. 1. pp. 94-102.
@article{550834792cb04b259b511d08eed84dee,
title = "A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis",
abstract = "Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, nonrandomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A total of 61 subjects with primary myelofibrosis or post–polycythemia vera/post–essential thrombocythemia myelofibrosis with intermediate- or high-risk disease received momelotinib. A phase 1 dose escalation identified 200 mg twice daily as the optimal dose to be expanded in phase 2. The most frequent adverse events were diarrhea (45.9{\%}), peripheral neuropathy (44.3{\%}), thrombocytopenia (39.3{\%}), and dizziness (36.1{\%}), the latter primarily due to a first-dose effect. The response assessment according to the 2006 International Working Group criteria (≥8 weeks duration at any time point) demonstrated spleen response by palpation of 72{\%} (36/50) and anemia response of 45{\%} (18/40). Spleen response by magnetic resonance imaging obtained at 24 weeks was 45.8{\%} (27/59) for all subjects and 54.0{\%} (27/50) for those with palpable splenomegaly at baseline. The symptoms of myelofibrosis were improved in most subjects. Cytokine analysis showed a rapid decline in interleukin-6 with momelotinib treatment, and a slower reduction in other inflammatory cytokines. In the subgroup of subjects with the JAK2V617F mutation at baseline (n=41), momelotinib significantly reduced the allele burden by 21.1{\%} (median) at 24 weeks. These results provide evidence of tolerability and a potential therapeutic activity of momelotinib for subjects that support further evaluation in ongoing, phase 3 randomized trials.",
author = "Vikas Gupta and Ruben Mesa and Deininger, {Michael W.N.} and Rivera, {Candido E.} and Shireen Sirhan and Brachmann, {Carrie Baker} and Helen Collins and Jun Kawashima and Yan Xin and Srdan Verstovsek",
year = "2017",
month = "1",
day = "1",
doi = "10.3324/haematol.2016.148924",
language = "English (US)",
volume = "102",
pages = "94--102",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "1",

}

TY - JOUR

T1 - A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis

AU - Gupta, Vikas

AU - Mesa, Ruben

AU - Deininger, Michael W.N.

AU - Rivera, Candido E.

AU - Sirhan, Shireen

AU - Brachmann, Carrie Baker

AU - Collins, Helen

AU - Kawashima, Jun

AU - Xin, Yan

AU - Verstovsek, Srdan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, nonrandomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A total of 61 subjects with primary myelofibrosis or post–polycythemia vera/post–essential thrombocythemia myelofibrosis with intermediate- or high-risk disease received momelotinib. A phase 1 dose escalation identified 200 mg twice daily as the optimal dose to be expanded in phase 2. The most frequent adverse events were diarrhea (45.9%), peripheral neuropathy (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%), the latter primarily due to a first-dose effect. The response assessment according to the 2006 International Working Group criteria (≥8 weeks duration at any time point) demonstrated spleen response by palpation of 72% (36/50) and anemia response of 45% (18/40). Spleen response by magnetic resonance imaging obtained at 24 weeks was 45.8% (27/59) for all subjects and 54.0% (27/50) for those with palpable splenomegaly at baseline. The symptoms of myelofibrosis were improved in most subjects. Cytokine analysis showed a rapid decline in interleukin-6 with momelotinib treatment, and a slower reduction in other inflammatory cytokines. In the subgroup of subjects with the JAK2V617F mutation at baseline (n=41), momelotinib significantly reduced the allele burden by 21.1% (median) at 24 weeks. These results provide evidence of tolerability and a potential therapeutic activity of momelotinib for subjects that support further evaluation in ongoing, phase 3 randomized trials.

AB - Momelotinib, a small-molecule inhibitor of Janus kinase 1 and Janus kinase 2, has demonstrated efficacy in myelofibrosis patients with 300 mg, once-daily dosing. This open-label, nonrandomized, phase 1/2 study evaluated the safety and therapeutic benefit of momelotinib with twice-daily dosing. A total of 61 subjects with primary myelofibrosis or post–polycythemia vera/post–essential thrombocythemia myelofibrosis with intermediate- or high-risk disease received momelotinib. A phase 1 dose escalation identified 200 mg twice daily as the optimal dose to be expanded in phase 2. The most frequent adverse events were diarrhea (45.9%), peripheral neuropathy (44.3%), thrombocytopenia (39.3%), and dizziness (36.1%), the latter primarily due to a first-dose effect. The response assessment according to the 2006 International Working Group criteria (≥8 weeks duration at any time point) demonstrated spleen response by palpation of 72% (36/50) and anemia response of 45% (18/40). Spleen response by magnetic resonance imaging obtained at 24 weeks was 45.8% (27/59) for all subjects and 54.0% (27/50) for those with palpable splenomegaly at baseline. The symptoms of myelofibrosis were improved in most subjects. Cytokine analysis showed a rapid decline in interleukin-6 with momelotinib treatment, and a slower reduction in other inflammatory cytokines. In the subgroup of subjects with the JAK2V617F mutation at baseline (n=41), momelotinib significantly reduced the allele burden by 21.1% (median) at 24 weeks. These results provide evidence of tolerability and a potential therapeutic activity of momelotinib for subjects that support further evaluation in ongoing, phase 3 randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=85008414144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008414144&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.148924

DO - 10.3324/haematol.2016.148924

M3 - Article

VL - 102

SP - 94

EP - 102

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 1

ER -